Physician profile
Daniel Lewis
NPI 1902821069
$4,842.30
in general payments reported to CMS, 2019-2025
37 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $396 · 2021: $910 · 2022: $963 · 2023: $783 · 2024: $610 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $642.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $372.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $362.79 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.22 | 2019-2025 | Jardiance |
| Amgen INC. | $265.11 | 2019-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $261.25 | 2022-2025 | Rexulti |
| Allergan, INC. | $254.75 | 2019-2021 | |
| Lilly USA, LLC | $233.68 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $227.75 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $221.83 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $216.39 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.74 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $117.95 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $102.58 | 2019-2021 | |
| Dexcom, INC. | $96.85 | 2021-2024 | Dexcom G6 Transmitter |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.